LETTER
Rapid Synthesis of 4-Benzyl-4-aminopiperidines
2567
A.; Schmatz, D. M.; Ellman, J. A. Bioorg. Med. Chem. Lett.
2005, 15, 345. (c) Jiang, X.; Song, Y.; Long, Y. Bioorg.
Med. Chem. Lett. 2004, 14, 3675; and references therein.
(2) (a) Micovic, I.; Ivanovic, M. D.; Vuckovic, S. M.; Prostran,
M. S.; Dosen-Micovic, L.; Kiricojevic, V. D. Bioorg. Med.
Chem. Lett. 2000, 10, 2011. (b) Chen, H. G.; Chung, F.-Z.;
Goel, O. P.; Johnson, D.; Kesten, S.; Knobelsdorf, J.; Lee, H.
T.; Rubin, J. R. Bioorg. Med. Chem. Lett. 1997, 5, 555.
(3) (a) Cossy, J.; Poitevin, C.; Gomez Pardo, D.; Peglion, J. L.;
Dessinges, A. Synlett 1998, 251. (b) Cossy, J.; Poitevin, C.;
Gomez Pardo, D. J. Org. Chem. 1998, 63, 4554.
10 with similar efficiency (41%) to the benzylic examples
(Scheme 4). Variation of the N-protecting group was test-
ed using N-tosylpiperidin-4-one (12). A similar reactivity
profile was observed to that of 1 in that only benzyl Grig-
nards were found to be effective nucleophiles (Scheme 4).
H
O
NH2
N
Ph
Ph
S
a
b
O
54%
67%
(c) Kudzma, L. V.; Severnak, S. A. S.; Benvenga, M. J.;
Ezell, E. F.; Ossipov, M. H.; Knight, V. V.; Rudo, F. G.;
Spencer, H. K.; Spaulding, T. C. J. Med. Chem. 1989, 32,
2534.
NH
NBoc
NBoc
7
8
9
H
N
O
NH2
(4) Palmer, R. A.; Salas, S.; Kouznetsov, V.; Stashenko, E.;
Montenegro, N. G.; Fontela, A. G. J. Heterocycl. Chem.
2001, 38, 837.
S
a
b
O
41%
94%
N
N
N
H
(5) Collins, I. J. Chem. Soc., Perkin Trans. 1 2002, 1921.
(6) (a) Brinner, K. M.; Ellman, J. A. Org. Biomol. Chem. 2005,
3, 2109. (b) Jiang, W.; Chen, C.; Marinkovic, D.; Tran, J. A.;
Chen, C. W.; Arellano, L. M.; White, N. S.; Tucci, F. C. J.
Org. Chem. 2005, 70, 8924. (c) McMahon, J. P.; Ellman, J.
A. Org. Lett. 2004, 6, 1645. (d) Mukade, T.; Dragoli, D. R.;
Ellman, J. A. J. Comb. Chem. 2003, 5, 590. (e) Shaw, A.
W.; deSolms, S. J. Tetrahedron Lett. 2001, 42, 7173.
(f) Ellman J. A., Owens T. D., Tang T. P.; Acc. Chem. Res.;
2002, 35: 984; and references therein.
Boc
Boc
1
10
11
O
S
O
S
O
N
N
HN
Ph
a
32%
N
N
Ts
Ts
Ts
(7) Compound 4: 1H NMR (500 MHz, DMSO): d = 1.11 (s, 9
H), 1.39 (s, 9 H), 1.66–1.69 (m, 4 H), 3.11–3.14 (m, 2 H),
3.45–3.50 (m, 2 H), 5.30 (s, 1 H), 5.52 (s, 1 H, signal
removed on addition of D2O). 13C NMR (125 MHz, DMSO):
d = 22.6, 28.1, 37.2, 38.0, 54.5, 78.5, 81.4, 153.8. MS (ES+):
m/z = 343 [M + Na+], 303 [M + H+ – H2O].
12
Scheme 4 Reagents and conditions: (a) tert-butylsulfinamide,
Ti(OEt)4, THF; then Grignard reagent, THF; (b) 4 M HCl in dioxane,
MeOH, r.t.
(8) (a) Conroy, J. L.; Sanders, T. C.; Seto, C. T. J. Am. Chem.
Soc. 1997, 119, 4285. (b) Burkey, T. J.; Fahey, R. C. J. Org.
Chem. 1985, 50, 1304.
(9) (a) Avenoza, A.; Busto, J. H.; Corzana, F.; Peregrina, J. M.;
Sucunza, D.; Zurbano, M. M. Synthesis 2005, 575.
(b) Mabic, S.; Cordi, A. A. Tetrahedron 2001, 57, 8861.
(10) (a) Kudzma, L. V.; Spencer, H. K.; Anaquest, S. A. S.
Tetrahedron Lett. 1988, 29, 6827. (b) Overman, L. E.;Burk,
R. M. Tetrahedron Lett. 1984, 25, 1635.
In summary, concise procedures for the synthesis of aryl
substituted 4-benzyl-4-aminopiperidines by the addition
of benzyl Grignard reagents to sulfinyl imines have been
developed, which show advantages over the more tradi-
tional Curtius approach in terms of the reduced number of
synthetic manipulations and are competitive in overall
yield. The hydration-prone tert-butanesulfinyl imine de-
rived from N-Boc-piperidin-4-one can be trapped as a
stable a-(N-sulfinyl)aminonitrile, which undergoes dis-
placement of the nitrile on treatment with Grignard re-
agents. Alternatively, benzyl and allyl Grignards will add
to the sulfinyl imine in situ in a one-pot procedure. Simple
acid deprotection provides various substituted 4-benzyl-
4-aminopiperidines which should prove useful scaffolds
for the synthesis of biologically active compounds.
(11) Kulinkovich, O. Eur. J. Org. Chem. 2004, 4517.
(12) Bartoli, G.; Bellucci, M.; Bosco, M.; Marcantoni, E.;
Sambri, L. Chem. Eur. J. 1998, 4, 2154.
(13) tert-Butyl 4-Cyano-4-(tert-butanesulfinamido)piper-
idine-1-carboxylate (5): A solution of N-Boc-piperidin-4-
one (1; 0.90 g, 4.52 mmol), tert-butanesulfinamide (0.58 g,
4.8 mmol) and Ti(OEt)4 (1.9 mL, 9 mmol) in anhyd THF (20
mL) was refluxed under N2 for 20 h. The red solution was
cooled, TMSCN (0.66 mL, 5 mmol) was added and the
solution was refluxed for 3 h. The cooled solution was
diluted with brine (20 mL) and EtOAc (20 mL). The
suspension was filtered through Celite, washing with further
EtOAc. The filtrate was separated and the organic layer was
dried (Na2SO4) and concentrated. Flash column
Acknowledgment
This work was supported by Cancer Research UK [CUK] grant
number C309/A2187. Additional funding was received from Astex
Therapeutics Ltd (JJC).
chromatography, eluting with EtOAc, gave 5 as a white
powder (0.851 g, 2.58 mmol, 57%). 1H NMR (500 MHz,
CDCl3): d = 1.26 (s, 9 H), 1.46 (s, 9 H), 1.70–1.78 (m, 1 H),
1.81–1.90 (m, 1 H), 2.20–2.30 (m, 2 H), 3.15–3.25 (m, 2 H),
3.65 (br s, 1 H), 3.95–4.15 (m, 2 H). 13C NMR (125 MHz,
CDCl3): d = 22.3, 28.4, 36.2, 37.5, 40.0, 56.9, 80.5, 119.6,
154.2. MS (ES+): m/z = 352 [M + Na+], 329 [M + H+].
tert-Butyl 4-Benzyl-4-(tert-butanesulfinamido)piper-
idine-1-carboxylate(6a); Via Nitrile 5: A solution of 5
(0.206 g, 0.625 mmol) and benzylmagnesium chloride (2 M
References and Notes
(1) For some recent examples of biologically active compounds
containing the 4-aminopiperidine motif, see: (a) Bamford,
M. J.; Bailey, N.; Davies, S.; Dean, D. K.; Francis, L.;
Panchal, T. A.; Parr, C. A.; Sehmi, S.; Steadman, J. G.;
Takle, A. K.; Townsend, J. T.; Wilson, D. M. Bioorg. Med.
Chem. Lett. 2005, 15, 3407. (b) Brinner, K. M.; Powles, M.
Synlett 2006, No. 16, 2565–2568 © Thieme Stuttgart · New York